{"denoms":[{"counts":[{"groupId":"BG000","value":"360"},{"groupId":"BG001","value":"357"},{"groupId":"BG002","value":"717"}],"units":"Participants"}],"groups":[{"description":"Patients will receive daunorubicin 60 mg/m\\^2 by IV push days 1-3 plus cytarabine 200 mg/m\\^2 IV days 1-7, and midostaurin 50 mg orally twice daily days 8-21. Participants achieving remission will receive four 28 day cycles of high dose cytarabine (3000 mg/m\\^2) days 1, 3, \\& 5 and midostaurin at 50 mg orally twice daily days 8-14. Maintenance therapy was given to participants who continued in remission for 12 28-day cycles of midostaurin 50 mg orally twice daily.","id":"BG000","title":"Induction and Consolidation Chemotherapy Plus Midostaurin"},{"description":"Patients will receive daunorubicin 60 mg/m\\^2 by IV push days 1-3 plus cytarabine 200 mg/m\\^2 IV days 1-7, and placebo 50 mg orally twice daily days 8-21. Participants achieving remission will receive four 28 day cycles of high dose cytarabine (3000 mg/m\\^2) days 1, 3, \\& 5 and placebo at 50 mg orally twice daily days 8-14. Maintenance therapy was given to participants who continued in remission for 12 28-day cycles of placebo 50 mg orally twice daily.","id":"BG001","title":"Induction and Consolidation Chemotherapy Plus Placebo"},{"description":"Total of all reporting groups","id":"BG002","title":"Total"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","lowerLimit":"19","upperLimit":"59.8","value":"47.1"},{"groupId":"BG001","lowerLimit":"18","upperLimit":"60.9","value":"48.6"},{"groupId":"BG002","lowerLimit":"18.0","upperLimit":"60.9","value":"47.9"}]}]}],"dispersionType":"FULL_RANGE","paramType":"MEDIAN","title":"Age, Continuous","unitOfMeasure":"years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"186"},{"groupId":"BG001","value":"212"},{"groupId":"BG002","value":"398"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"174"},{"groupId":"BG001","value":"145"},{"groupId":"BG002","value":"319"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"9"},{"groupId":"BG001","value":"7"},{"groupId":"BG002","value":"16"}],"title":"Hispanic or Latino"},{"measurements":[{"groupId":"BG000","value":"103"},{"groupId":"BG001","value":"107"},{"groupId":"BG002","value":"210"}],"title":"Not Hispanic or Latino"},{"measurements":[{"groupId":"BG000","value":"248"},{"groupId":"BG001","value":"243"},{"groupId":"BG002","value":"491"}],"title":"Unknown or Not Reported"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Ethnicity (NIH/OMB)","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"1"}],"title":"American Indian or Alaska Native"},{"measurements":[{"groupId":"BG000","value":"8"},{"groupId":"BG001","value":"5"},{"groupId":"BG002","value":"13"}],"title":"Asian"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}],"title":"Native Hawaiian or Other Pacific Islander"},{"measurements":[{"groupId":"BG000","value":"8"},{"groupId":"BG001","value":"9"},{"groupId":"BG002","value":"17"}],"title":"Black or African American"},{"measurements":[{"groupId":"BG000","value":"147"},{"groupId":"BG001","value":"128"},{"groupId":"BG002","value":"275"}],"title":"White"},{"measurements":[{"groupId":"BG000","value":"2"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"3"}],"title":"More than one race"},{"measurements":[{"groupId":"BG000","value":"195"},{"groupId":"BG001","value":"213"},{"groupId":"BG002","value":"408"}],"title":"Unknown or Not Reported"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Race (NIH/OMB)","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"4"},{"groupId":"BG001","value":"9"},{"groupId":"BG002","value":"13"}]}],"title":"Canada"},{"categories":[{"measurements":[{"groupId":"BG000","value":"117"},{"groupId":"BG001","value":"106"},{"groupId":"BG002","value":"223"}]}],"title":"United States"},{"categories":[{"measurements":[{"groupId":"BG000","value":"148"},{"groupId":"BG001","value":"157"},{"groupId":"BG002","value":"305"}]}],"title":"Germany"},{"categories":[{"measurements":[{"groupId":"BG000","value":"3"},{"groupId":"BG001","value":"5"},{"groupId":"BG002","value":"8"}]}],"title":"Belgium"},{"categories":[{"measurements":[{"groupId":"BG000","value":"3"},{"groupId":"BG001","value":"2"},{"groupId":"BG002","value":"5"}]}],"title":"France"},{"categories":[{"measurements":[{"groupId":"BG000","value":"3"},{"groupId":"BG001","value":"2"},{"groupId":"BG002","value":"5"}]}],"title":"Netherlands"},{"categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"2"},{"groupId":"BG002","value":"2"}]}],"title":"Australia"},{"categories":[{"measurements":[{"groupId":"BG000","value":"7"},{"groupId":"BG001","value":"15"},{"groupId":"BG002","value":"22"}]}],"title":"Spain"},{"categories":[{"measurements":[{"groupId":"BG000","value":"7"},{"groupId":"BG001","value":"5"},{"groupId":"BG002","value":"12"}]}],"title":"Austria"},{"categories":[{"measurements":[{"groupId":"BG000","value":"61"},{"groupId":"BG001","value":"44"},{"groupId":"BG002","value":"105"}]}],"title":"Italy"},{"categories":[{"measurements":[{"groupId":"BG000","value":"5"},{"groupId":"BG001","value":"6"},{"groupId":"BG002","value":"11"}]}],"title":"Czech Republic"},{"categories":[{"measurements":[{"groupId":"BG000","value":"2"},{"groupId":"BG001","value":"2"},{"groupId":"BG002","value":"4"}]}],"title":"Slovakia"},{"categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"2"},{"groupId":"BG002","value":"2"}]}],"title":"Hungary"}],"paramType":"NUMBER","title":"Region of Enrollment","unitOfMeasure":"participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"81"},{"groupId":"BG001","value":"81"},{"groupId":"BG002","value":"162"}]}],"title":"TKD (No ITD)"},{"categories":[{"measurements":[{"groupId":"BG000","value":"171"},{"groupId":"BG001","value":"170"},{"groupId":"BG002","value":"341"}]}],"title":"ITD Allelic ratio <0.7"},{"categories":[{"measurements":[{"groupId":"BG000","value":"108"},{"groupId":"BG001","value":"106"},{"groupId":"BG002","value":"214"}]}],"title":"ITD Allelic ratio >=0.7"}],"description":"Mutations in the gene encoding the trans-membrane tyrosine kinase FLT3. FLT3 internal tandem duplications (ITD) mutation which results in a duplication between 3 and greater than 100 amino acids most commonly located in the juxtamembrane region. Tyrosine kinase domain (TKD) point mutations are the remainder of those with FLT3 mutations. FLT3 testing was done centrally.","paramType":"NUMBER","title":"FLT3 mutational subtype","unitOfMeasure":"participants"}]}